Biblio
“Fertility-sparing treatment for intramucous, moderately differentiated, endometrioid endometrial cancer: a Gynecologic Cancer Inter-Group (GCIG) study”, Journal of Gynecologic Oncology, vol. 31, 2020.
, “Early tumor regrowth is a contributor to impaired survival in patients with completely resected advanced ovarian cancer. An exploratory analysis of the Intergroup trial AGO-OVAR 12.”, Gynecol Oncol, vol. 152, no. 2, pp. 235-242, 2019.
, “Final results from GCIG/ENGOT/AGO‐OVAR 12, a randomised placebo‐controlled phase III trial of nintedanib combined with chemotherapy for newly diagnosed advanced ovarian cancer”, International Journal of Cancer, vol. 146, no. 2, pp. 439 - 448, 2019.
, “A GCIG international survey: clinical practice patterns of sentinel lymph node biopsies in cervical cancer.”, Arch Gynecol Obstet, 2019.
, “Gynecological Cancers Translational, Research Implementation, and Harmonization: Gynecologic Cancer InterGroup Consensus and Still Open Questions.”, Cells, vol. 8, no. 3, 2019.
, “Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer”, New England Journal of Medicine, vol. 381, no. 25, pp. 2416 - 2428, 2019.
, “Overall survival results of AGO-OVAR16: A phase 3 study of maintenance pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced ovarian cancer”, Gynecologic Oncology, vol. 155, no. 2, pp. 186 - 191, 2019.
, “A Randomized Trial of Lymphadenectomy in Patients with Advanced Ovarian Neoplasms.”, N Engl J Med, vol. 380, no. 9, pp. 822-832, 2019.
, “SENTICOL III: an international validation study of sentinel node biopsy in early cervical cancer. A GINECO, ENGOT, GCIG and multicenter study”, International Journal of Gynecologic Cancer, vol. 29, no. 4, pp. 829 - 834, 2019.
, “TRUST: Trial of Radical Upfront Surgical Therapy in advanced ovarian cancer (ENGOT ov33/AGO‐OVAR OP7)”, International Journal of Gynecologic Cancer, vol. 29, no. 8, pp. 1327 - 1331, 2019.
, ,
“Adjuvant therapy for women with high-risk endometrial carcinoma.”, Lancet Oncol, 2018.
, “Advancing clinical research globally: Cervical cancer research network from Mexico.”, Gynecol Oncol Rep, vol. 25, pp. 90-93, 2018.
, “Commonly Occurring Cell Subsets in High-Grade Serous Ovarian Tumors Identified by Single-Cell Mass Cytometry.”, Cell Rep, vol. 22, no. 7, pp. 1875-1888, 2018.
, “Minimally Invasive versus Abdominal Radical Hysterectomy for Cervical Cancer.”, N Engl J Med, vol. 379, no. 20, pp. 1895-1904, 2018.
, “Quality of life in patients with advanced epithelial ovarian cancer (EOC) randomized to maintenance pazopanib or placebo after first-line chemotherapy in the AGO-OVAR 16 trial.”, Ann Oncol, vol. 29, no. 3, pp. 737-743, 2018.
, “Too many women are dying from cervix cancer: Problems and solutions.”, Gynecol Oncol, 2018.
, “Cervical cancer: A global health crisis.”, Cancer, vol. 123, no. 13, pp. 2404-2412, 2017.
, “Fifth Ovarian Cancer Consensus Conference: individualized therapy and patient factors”, Annals of Oncology, vol. 28, no. 4, pp. 702 - 710, 2017.
, “Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: Recommendations on incorporating patient-reported outcomes in clinical trials in epithelial ovarian cancer”, European Journal of Cancer, vol. 78, pp. 133 - 138, 2017.
, “Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: first-line interventions”, Annals of Oncology, vol. 28, no. 4, pp. 711 - 717, 2017.
, “Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: recurrent disease”, Annals of Oncology, vol. 28, no. 4, pp. 727 - 732, 2017.
, “Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup (GCIG): clinical trial design for rare ovarian tumours”, Annals of Oncology, vol. 28, no. 4, pp. 718 - 726, 2017.
, “Harmonising clinical trials within the Gynecologic Cancer InterGroup: consensus and unmet needs from the Fifth Ovarian Cancer Consensus Conference.”, Ann Oncol, vol. 28, no. suppl_8, pp. viii30-viii35, 2017.
, “Harmonising clinical trials within the Gynecologic Cancer InterGroup: consensus and unmet needs from the Fifth Ovarian Cancer Consensus Conference”, Annals of Oncology, vol. 28, pp. viii30 - viii35, 2017.
,